UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 14C

             INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

Check the appropriate box:
[X] Preliminary Information Statement
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
    14c-5(d)(2))
[ ] Definitive Information Statement


                     Stem Cell Therapy International, Inc.
--------------------------------------------------------------------------------
                (Name of Registrant as Specified in its Charter)

Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14C-5(g) and 0-11.

(1) Title of each class of securities to which transaction applies:

--------------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:

--------------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (Set forth the amount of which the filing fee is
calculated and state how it was determined):

--------------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:

--------------------------------------------------------------------------------
(5) Total fee paid:

--------------------------------------------------------------------------------

[  ] Fee paid previously with preliminary materials.
[  ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.

1) Amount previously paid:_________________________________

2) Form, Schedule or Registration Statement No.:_________________

3) Filing Party:___________________________________________

4) Date Filed:___________________________________________

--------------------------------------------------------------------------------

                                        1

                      Stem Cell Therapy International, Inc
                            13406 Racetrack Rd, #233
                                Tampa, FL 33626

                             INFORMATION STATEMENT

        Pursuant To Section 14(c) of Securities and Exchange Act Of 1934

                 Approximate Date of Mailing: November 3, 2009

                       WE ARE NOT ASKING YOU FOR A PROXY
                  AND YOU ARE REQUESTED NOT TO SEND US A PROXY

This  information Statement is being furnished by the Board of Directors of Stem
Cell  Therapy  International, Inc. (the "Company") to the stockholders of record
of  the  Company's common stock at the close of business on October 1, 2009 (the
"Record  Date"), and is being sent to you to inform you of action which has been
approved  by  the  holders  of  at  least  a majority of the voting power of the
Company  outstanding  on  the Record Date, by written consents without holding a
meeting  of  stockholders.  By such written consents, such stockholders approved
the  following  action:

1.   To amend  our  Articles  of  Incorporation  to  effect  an  increase in the
     Company's  authorized  shares  of  common  stock  to  five  hundred million
     (500,000,000)  shares.

2.   To change  the name of the Company to AmStem Corporation (the "Amendment").

Our  Board of Directors unanimously adopted and approved the proposal on October
1,  2009,  and on or about October 22, 2009, we received the written consent, in
lieu  of  a  meeting  of  stockholders,  from  the  holders of a majority of the
outstanding  shares with the right to vote on these matters. No other votes were
required  to adopt the Amendment and none are being solicited hereunder.  A copy
of  the  Certificate  of  Amendment to the Articles of Incorporation is attached
hereto  as  Exhibit  "A".
            ------------

This Information Statement is first being mailed or furnished to stockholders on
or  about  November  3, 2009, and the Amendment described herein will not become
effective  until  at least twenty (20) calendar days thereafter. We will pay all
costs  associated  with  the  preparation  and  distribution of this Information
Statement,  including  all  mailing  and  printing  expenses.

--------------------------------------------------------------------------------
NO  VOTE  OR  OTHER  CONSENT OF OUR STOCKHOLDERS IS SOLICITED IN CONNECTION WITH
THIS  INFORMATION  STATEMENT.  WE  ARE  NOT  ASKING  YOU FOR A PROXY AND YOU ARE
REQUESTED  NOT  TO  SEND  US  A  PROXY.
--------------------------------------------------------------------------------



                                        2

                    OUTSTANDING SECURITIES AND VOTING RIGHTS

As  of  October  1,  2009,  the  Company  had authorized:(1) one hundred million
(100,000,000) shares of common stock, $0.001 par value, 54,260,611 of which were
issued  and  outstanding,  and  (2) ten million (10,000,000) shares of preferred
stock,  $0.001  par  value,  of  which  none  are  issued  and  outstanding.

Each  holder  of  Common  Stock is entitled to one vote for each share of Common
Stock  held  on all matters submitted to a vote of Stockholders.  However, under
Nevada  law,  any  action  that may be taken at any stockholders' meeting may be
taken  by  written  consent  of the requisite number of stockholders required to
take  such  action.  The  Amendment  requires  the  affirmative  vote or written
consent  of  the holders of a majority of the Company's outstanding common stock
and  Series  A  Preferred  stock.

                              STOCKHOLDERS' RIGHTS

The elimination of the need for a special meeting of the stockholders to approve
the  actions  proposed and discussed in this Information Statement is authorized
by  Section  78.320(2) of the Nevada Revised Statutes (the "NRS").  This section
provides  that  any  action  required  or  permitted to be taken at a meeting of
stockholders  of  a  corporation may be taken without a meeting, before or after
the  action,  if a written consent thereto is signed by the stockholders holding
at  least  a  majority  of  the  voting  power.

In  order  to  eliminate  the  costs  and  management time involved in holding a
special  meeting  and  in  order  to effect the proposed resolutions as early as
possible  in  order to accomplish the purposes of the Company, the Company chose
to  obtain  the  written  consent  of its stockholders holding a majority of the
Company's  voting  power.

The  action  described  in  this  Information Statement cannot be taken until at
least  20  days  after  this  Information Statement has been first mailed to the
Company's  stockholders.

                             NO DISSENTERS' RIGHTS

The  NRS  does  not provide for dissenter's rights in connection with any of the
actions  proposed  in  this  Information  Statement.


                                        3

                                 THE AMENDMENTS

GENERAL

The  Board  has  approved,  and the stockholders owning a majority of the shares
entitled  to  vote  on  matters  submitted to the stockholders have consented in
writing  to amend the Company's Articles of Incorporation to increase the number
of  authorized  shares  of  Common  Stock  to five hundred million (500,000,000)
shares  and  to  change  the  name  of  the  Company  to  AmStem  Corporation.

A copy of the Articles of Amendment effecting the change in authorized shares of
Common Stock and the name change, in substantially the form to be filed with the
Secretary  of  State  of  Nevada,  is  attached to this Information Statement as
Exhibit  "A".  The  stockholders owning a majority of the issued and outstanding
shares  of  the Common Stock have consented to the increase in authorized shares
of  Common  Stock,  which  will  become  effective  on  November  23,  2009 (the
"Effective  Date").

The  Company  has  taken  all  action  required  under Nevada law to approve the
Amendment;  however, since stockholder approval of the Amendment was obtained by
written consent rather than at a stockholders' meeting, Nevada law requires that
notice  be sent to all non-consenting stockholders notifying them of the actions
taken  not  more  than  30  days after the effective date of the consent and the
Exchange  Act  will  not  permit such filing until the expiration of 20 calendar
days  from  the  date  hereof.  The  Articles of Amendment filed with the Nevada
Secretary of State will not become effective until the Effective Date, after the
expiration  of  the  20-calendar  day  period.

STOCKHOLDER APPROVAL PREVIOUSLY OBTAINED

As  of October 1, 2009, the Company had 54,260,611 issued and outstanding shares
of  Common  Stock  and  no  issued  and outstanding shares of Series A Preferred
Stock.  Each  holder  of  Common Stock is entitled to one vote for each share of
Common  Stock  held  on  all  matters  submitted  to  a  vote  of  stockholders.

By  written  consent dated October 1, 2009 the stockholders owning a majority of
the  outstanding  stock  entitled  to  vote  have  approved  the  adoption  and
implementation  of  the  Amendment.  Such  action  is  sufficient to satisfy the
applicable  requirements  of  Nevada law that stockholders approve such actions.
Accordingly,  stockholders  will  not  be  asked  to  take further action on the
Amendment  at  any  future meeting and the Board of Directors does not intend to
solicit  any  proxies or consents from any other stockholders in connection with
the  Amendment.

PURPOSE AND EFFECT OF INCREASE IN COMMON STOCK AND PREFERRED STOCK

The  increase  of  authorized  common  stock  will  provide the Company with the
ability  to  issue  capital  stock  in  connection  with  any  future  financing
activities  or  corporate  mergers  and acquisitions using the Company's capital
stock.

                                        4

When  issued,  the additional shares of common stock authorized by the amendment
will have the same rights and privileges as the shares of common stock currently
authorized  and  outstanding.  Holders of common stock have no preemptive rights
and,  accordingly,  shareholders  would  not  have  any  preferential  rights to
purchase  any  of  the  additional  shares  of common stock when such shares are
issued.

Having  a  substantial  number of authorized but unissued shares of common stock
that  are not reserved for specific purposes will allow us to take prompt action
with  respect  to  corporate  opportunities  that develop, without the delay and
expense  of  convening  an  annual  meeting  of  shareholders for the purpose of
approving  an  increase  in  the  Company's  capitalization.  The  issuance  of
additional  shares  of  common stock may, depending upon the circumstances under
which  such  shares  are  issued,  reduce shareholders' equity per share and may
reduce the percentage ownership of common stock by existing shareholders.  It is
not the present intention of the Board of Directors to seek shareholder approval
prior  to any issuance of shares of common stock that would become authorized by
the  amendment  unless  otherwise  required  by  law  or  regulation.

The  increase  in  the authorized number of shares of the Company's common stock
under  the  amendment  could  be  used  by  its  Board of Directors to make more
difficult,  and  thereby  discourage,  delay  or  prevent, an attempt to acquire
control  of the Company.  For example, the shares could be privately placed with
purchasers  who  might  support  the  Company's Board of Directors in opposing a
hostile  takeover  bid.  The  issuance  of  the new shares also could be used to
dilute  the  stock ownership and voting power of a third party seeking to remove
directors, replace incumbent directors, accomplish certain business combinations
or  alter, amend or repeal provisions of the Company's articles of incorporation
or  bylaws.  To  the  extent  that it impedes any such attempts, the issuance of
shares  following the adoption of the amendment may serve to perpetuate existing
management.  While  the amendment may have potential antitakeover effects, it is
not  prompted  by  any specific effort or takeover threat currently perceived by
the  Company's  Board of Directors or management.  Although under Nevada law our
Board  of  Directors  is  required to make any determination to issue such stock
based on its judgment as to the best interests of its shareholders, its Board of
Directors  could act in a manner that would discourage an acquisition attempt or
other transaction that some, or a majority, of its shareholders might believe to
be  in their best interests or in which shareholders might receive a premium for
their  stock  over  the  then  market  price  of  such  stock.

PURPOSE AND EFFECT OF NAME CHANGE

The  Company  has changed its name to better reflect the ongoing business of the
Company.

                           EFFECTIVENESS OF AMENDMENT

The  Company  reserves  the  right,  upon  notice to stockholders, to abandon or
modify  the  proposed Amendment at any time prior to the filing of the Amendment
upon  consent  of  the Board and the holders of a majority of the existing stock
entitled  to  vote  on  matters  submitted  to  the  stockholders.

                                        5

            INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON

No director, executive officer, nominee for election as a director, associate of
any  director,  executive  officer  or  nominee  or  any  other  person  has any
substantial  interest,  direct  or  indirect, by security holdings or otherwise,
resulting  from  the  matters described herein, which is not shared by all other
stockholders  pro-rata,  and  in  accordance  with  their  respective interests.

          SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS AND MANAGEMENT

The  following table sets forth information with respect to beneficial ownership
of  the  Company's  outstanding  Common Stock as of October 1, 2009 by: (1) each
person  known by the Company to beneficially own more than 5% of the outstanding
Common  Stock,  (2)  each of the Company's named executive officers, (3) each of
the  Company's  directors,  and  (4) all of the Company's executive officers and
directors  as  a  group.

Beneficial  ownership  is  determined  in  accordance with the rules of the SEC.
Except  as  otherwise  noted, the persons or entities named have sole voting and
investment power with respect to all shares shown as beneficially owned by them.

The  table  shows  each  person known to us who owns beneficially more than five
percent of the outstanding common stock of Stem Cell Therapy International, Inc.
based  on  42,139,177  shares  being  outstanding as of October 1, 2009, and the
total  amount  of common stock of Stem Cell Therapy International, Inc. owned by
each  of  its  Directors and Executive Officers and for all of its Directors and
Executive  Officers  as  a  group.

                                                         PERCENTAGE
NAME AND ADDRESS OR           NUMBER OF SHARES   CLASS   OF CLASS
----------------------------  -----------------  ------  -----------
Calvin C. Cao
2203 N. Lois Avenue,
9th Floor
Tampa, FL  33607                  7,904,200 (1)  Common        14.6%

Andrew J. Norstrud
15837 Trackside Dr
Odessa, FL 33556                  2,400,000 (2)  Common         4.3%

David J. Stark
13406 Racetrack Rd, #233
Tampa, FL 33626                      3,063,942   Common         5.5%

Lixian (John) Jiang
13406 Racetrack Rd, #233
Tampa, FL 33626                        950,000   Common         1.7%

All Directors and Executive
Officers as a Group
(3 persons)                          6,413,942   Common        11.0%

(1)  Consists  of  702,200 shares held by Global Capital Corp., 2,000,000 shares
     held  by  Vivian  Cao  Irrevocable  Trust  and  2,000,000  shares  held  by
     Christopher  Cao  Irrevocable  Trust  and 2,702,000 shares held by Thuy-Van
     Chau  (the  spouse  of  Mr.  Cao).  Mr.  Cao was previously President and a
     Director  of  the  Company  but  has  subsequently  resigned.

                                        6

(2)   Consists  of  1,000,000  shares  directly  owned,  1,000,000  warrants  to
     purchase  shares  at $.15 per share and 400,000 warrants to purchase shares
     at  $.19  per  share.
(3)  Consists of 1,263,942 shares directly owned, 1,000,000 warrants to purchase
     shares  at  $.15  per share and 750,000 warrants to purchase shares at $.25
     per  share.
(4)  Consists of 250,000 shares directly owned, and 700,000 warrants to purchase
     shares  at  $.19  per  share.


                                  OTHER ACTION

No other action was taken or authorized by the stockholders' written consent to
corporate action to which this Information Statement pertains.

                         COSTS OF INFORMATION STATEMENT

This  Information  Statement  has  been prepared by the Company and its Board of
Directors.  The  Company  will  bear  the costs of distributing this Information
Statement  to  stockholders,  including  the  expense  of preparing, assembling,
printing  and  mailing  the  Information Statement.  Although there is no formal
agreement to do so, the Company may reimburse attorneys, banks, brokerage houses
and  other custodians, nominees and fiduciaries for their reasonable expenses in
forwarding  this  Information  Statement  and related materials to stockholders.
The  Company  may pay for and use the services of other individuals or companies
not  regularly  employed  by  the Company in connection with the distribution of
this  Information  Statement if the Board of Directors of the Company determines
that  this  is  advisable.

By Order of the Board of Directors

/s/David Stark
--------------
David Stark, Chairman of the Board of Directors, President  and CEO










                                        7

                                  EXHIBIT "A"
DEAN HELLER
Secretary of State
204 North Carson Street, Suite 1
Carson City, Nevada 89701-4299
(775) 684-5708
Website:  secretaryofstate.biz

---------------------------------------------------------
Certificate of Amendment
(Pursuant to NRS 78.385 and 78.390)
---------------------------------------------------------

             Certificate of Amendment to Articles of Incorporation
                         For Nevada Profit Corporation

         (Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)

1.     Name of corporation:

Stem Cell Therapy International, Inc.

2.     The articles have been amended as follows (provide article numbers, if
available):

FIRST:  The name of the Corporation is AmStem Corporation.



FOURTH.  The  voting  common  stock  authorized  may be issued by the
corporation is FIVE HUNDRED MILLION (500,000,000) shares of stock with a normal
par  value  of  .001  per share and no other class of stock shall be authorized.
Said shares with nominal or par value may be issued by the corporation from time
to time  for such considerations as may be fixed from time to time by the Board
of  Directors.

3.     The vote by which the stockholders holding shares in the corporation
entitling them to exercise at least a majority of the voting power, or such
greater proportion of the voting power as may be required in the case of a vote
by classes or series, or as may be required by the provisions of the articles of
incorporation have voted in favor of the amendment is:  a majority of those
authorized

4.     Effective date of filing (optional):

5.     Officer signature (required):  /s/David Stark
                                      --------------

*If any proposed amendment would alter or change any preference or any relative
or other right given to any class or series of outstanding shares, then the
amendment must be approved by the vote, in addition to the affirmative vote
otherwise required, of the holders of the shares representing a majority of the
voting power of each class or series affected by the amendment regardless of
limitations or restrictions on the voting power thereof.

IMPORTANT:  Failure to include any of the above information and submit the
proper fees may cause this filing to be rejected.






                                        8